Imatinib and beyond—the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

Author： Berger U.  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.83, Iss.4, 2004-04, pp. : 258-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

By Koh Youngil   Kim Inho   Yoon Sung-Soo   Kim Byoung   Kim Dae-Young   Lee Je-Hwan   Lee Kyoo-Hyung   Park Eunkyung   Kim Hyeoung-Joon   Sohn Sang   Joo Young   Kim Seok   Chung Jooseop   Shin Ho-Jin   Kim Sung-Hyun   Kim Chul   Song Hong   Kim Min   Hyun Myung   Ahn Jin   Jung Chul   Park Seonyang  

Annals of Hematology, Vol. 89, Iss. 7, 2010-07 ,pp. : 725-731

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

By Deenik W.   Holt B.   Verhoef G.   Schattenberg A.   Verdonck L.   Daenen S.   Zachée P.   Westveer P.   Smit W.   Wittebol S.   Schouten H.   Löwenberg B.   Ossenkoppele G.   Cornelissen J.  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 117-125

Springer Publishing Company

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

By Usuki Kensuke  

International Journal of Hematology, Vol. 95, Iss. 4, 2012-04 ,pp. : 409-419

Springer Publishing Company

Access to resources Recommend Favorite